Request Demo
Last update 06 Dec 2025
Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)
Last update 06 Dec 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms 重组抗人肿瘤坏死因子（TNFα）单抗(华兰基因工程), HL 01, HL-01 + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 26792L
The sequence is quoted from: *****
Sequence Code 88699H
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)CTR20200016
多中心、随机、双盲、平行对照HL01与原研药修美乐在中重度活动性类风湿关节炎患者中疗效和安全性的Ⅲ期研究
[Translation] A multicenter, randomized, double-blind, parallel controlled Phase III study on the efficacy and safety of HL01 and the original drug Humira in patients with moderately to severely active rheumatoid arthritis
CTR20180539
在中国健康男性受试者中比较HL01与修美乐单次皮下注射给药的生物等效性和安全性的临床研究
[Translation] A clinical study comparing the bioequivalence and safety of HL01 and Humira after a single subcutaneous injection in healthy Chinese male subjects
100 Clinical Results associated with Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Translational Medicine associated with Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Patents (Medical) associated with Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Deals associated with Adalimumab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ankylosing Spondylitis | Phase 3 | China | 18 May 2020 | |
| Psoriasis | Phase 3 | China | 18 May 2020 | |
| Rheumatoid Arthritis | Phase 3 | China | 18 May 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free